NCT00024076

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

Radiofrequency Ablation of Pulmonary Malignancy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Jonsson Comprehensive Cancer Center · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.

Detailed description

OBJECTIVES: * Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies. * Determine the efficacy of this treatment, in terms of local control, in these patients. * Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients. OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours. Patients are followed at 1, 3, 6, and 12 months. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Conditions

• Lung Cancer
• Malignant Mesothelioma
• Metastatic Cancer
• Thymoma and Thymic Carcinoma

Interventions

Type	Name	Description
PROCEDURE	radiofrequency ablation

Timeline

• Start date: 2000-05-01
• Primary completion: 2006-12-01
• First posted: 2003-01-27
• Last updated: 2020-08-03

Locations

1 site across 1 country: United States